Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders - UpToDate

INTRODUCTION The Janus kinases (JAKs) are protein tyrosine kinases (TYKs) that bind to transmembrane type 1 and type 2 cytokine receptors and mediate cellular responses to numerous cytokines and growth factors; these mediators are important in immune defense and in immune-mediated disease. Several pharmacologic JAK inhibitors (JAKi or Jakinibs) are commercially available for clinical use as oral and topical agents for immune-mediated and inflammatory diseases, although the availability of various JAK inhibitors varies among countries and regions. JAK inhibitors are highly targeted molecules with relatively simple chemical structures in comparison to therapeutic agents made by recombinant deoxyribonucleic acid (DNA) techniques (and thus termed "biologics"), such as monoclonal antibodies and soluble truncated membrane receptors. Unlike biologics, the JAK inhibitors can be orally administered, although some are available for topical use. Major established and investigational uses of JAK i

INTRODUCTION The Janus kinases (JAKs) are protein tyrosine kinases (TYKs) that bind to transmembrane type 1 and type 2 cytokine receptors and mediate cellular responses to numerous cytokines and growth factors; these mediators are important in immune defense and in immune-mediated disease. Several pharmacologic JAK inhibitors (JAKi or Jakinibs) are commercially available for clinical use as oral and topical agents for immune-mediated and inflammatory diseases, although the availability of various JAK inhibitors varies among countries and regions. JAK inhibitors are highly targeted molecules wi